X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (106) 106
index medicus (66) 66
melanoma (62) 62
female (51) 51
oncology (51) 51
male (48) 48
middle aged (42) 42
aged (41) 41
dermatology (40) 40
skin neoplasms - pathology (38) 38
adult (34) 34
cancer (34) 34
melanoma - pathology (31) 31
immunotherapy (28) 28
care and treatment (27) 27
metastasis (26) 26
skin cancer (24) 24
610 medicine & health (23) 23
aged, 80 and over (23) 23
dermatology clinic (22) 22
skin neoplasms - drug therapy (22) 22
melanoma - drug therapy (21) 21
metastatic melanoma (20) 20
skin (20) 20
melanoma - genetics (19) 19
therapy (19) 19
treatment outcome (19) 19
tumors (19) 19
immunology (18) 18
analysis (17) 17
medicine, research & experimental (17) 17
neoplasm staging (15) 15
chemotherapy (14) 14
expression (14) 14
immunohistochemistry (14) 14
ipilimumab (14) 14
melanoma - immunology (14) 14
mutation (14) 14
patients (14) 14
survival (14) 14
animals (13) 13
clinical trials (13) 13
hematology, oncology and palliative medicine (13) 13
melanoma - therapy (13) 13
metastases (13) 13
gene expression (12) 12
adolescent (11) 11
antineoplastic agents - adverse effects (11) 11
antineoplastic agents - therapeutic use (11) 11
cell biology (11) 11
dermatology & venereal diseases (11) 11
disease-free survival (11) 11
lymphoma, t-cell, cutaneous - pathology (11) 11
malignant-melanoma (11) 11
t-cell lymphoma (11) 11
article (10) 10
disease progression (10) 10
melanoma - secondary (10) 10
mice (10) 10
research (10) 10
safety (10) 10
time factors (10) 10
drug therapy (9) 9
follow-up studies (9) 9
lymphoma, b-cell - pathology (9) 9
lymphomas (9) 9
prognosis (9) 9
proteins (9) 9
skin neoplasms - diagnosis (9) 9
young adult (9) 9
antineoplastic agents - administration & dosage (8) 8
apoptosis (8) 8
cell line, tumor (8) 8
genetic aspects (8) 8
health aspects (8) 8
medical research (8) 8
mutations (8) 8
neoplasm metastasis (8) 8
pembrolizumab (8) 8
proto-oncogene proteins b-raf - genetics (8) 8
sezary-syndrome (8) 8
skin neoplasms - genetics (8) 8
tumor cells, cultured (8) 8
vemurafenib (8) 8
antineoplastic agents (7) 7
basal cell carcinoma (7) 7
biomarkers (7) 7
cancer therapies (7) 7
cutaneous melanoma (7) 7
efficacy (7) 7
kaplan-meier estimate (7) 7
lymphoma, t-cell, cutaneous - drug therapy (7) 7
medicine & public health (7) 7
melanoma - metabolism (7) 7
melanoma - mortality (7) 7
mycosis-fungoides (7) 7
nivolumab (7) 7
open-label (7) 7
skin neoplasms - therapy (7) 7
studies (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 113 - 125.e5
Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell... 
Dermatology | Basal Cell Carcinoma Outcomes with LDE225 Treatment study | hedgehog pathway inhibitor | sonidegib | locally advanced basal cell carcinoma | metastatic basal cell carcinoma | advanced basal cell carcinoma | Locally advanced basal cell carcinoma | Advanced basal cell carcinoma | Metastatic basal cell carcinoma | Sonidegib | Hedgehog pathway inhibitor | HEDGEHOG PATHWAY | MULTICENTER | VISMODEGIB | MANAGEMENT | EFFICACY | GUIDELINES | OPEN-LABEL | DERMATOLOGY | DOSE-ESCALATION | UPDATE | INHIBITOR | Skin Neoplasms - drug therapy | Humans | Middle Aged | Carcinoma, Basal Cell - secondary | Biphenyl Compounds - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Biphenyl Compounds - therapeutic use | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Smoothened Receptor - antagonists & inhibitors | Pyridines - therapeutic use | Skin Neoplasms - pathology | Pyridines - administration & dosage | Double-Blind Method | Survival Rate | Disease Progression | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical research | Care and treatment | Basal cell carcinoma | Analysis | Patient outcomes | Corn | Medicine, Experimental | Skin | Metastasis | Drug therapy | Cancer
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2013, Volume 69, Issue 4, pp. 530 - 536
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10094, pp. 555 - 566
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 435 - 445
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Journal Article